Under the deal, Megapharm will seek regulatory approval for Fanapt, and Vanda will supply Megapharm with Fanapt drug product for packaging and sale in Israel.
Vanda CEO Mihael Polymeropoulos said they have been active in the CNS field for many years and are happy to have the opportunity to launch an important antipsychotic product, that will strengthen its presence and expand portfolio in this therapeutic area.
”We are proud that Vanda has chosen us to introduce such an important treatment option for patients who suffer from the symptoms of Schizophrenia," Polymeropoulos added.
Vanda Pharmaceuticals is a biopharmaceutical company, that specialises on the development and commercialization of products for central nervous system disorders.